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Background: Stroke is the fifth leading cause of death and the primary cause of long-term adult disability in the
United States. Increasing evidence suggests that low T3 levels immediately following acute ischemic stroke are
associated with greater stroke severity, higher mortality rates, and poorer functional outcomes. Prognosis is also
poor in critically ill hospitalized patients who have non-thyroidal illness syndrome (NTIS), where T3 levels are low,
but TSH is normal. However, data regarding the association between TSH levels and functional outcomes are
contradictory. Thus, this study investigated the role of TSH on stroke outcomes, concomitantly with T3 and T4.
Findings: In this work, blood was collected from patients with radiologically confirmed acute ischemic stroke at 24
±6 hours post-symptom onset and serum levels of TSH, free T3, and free T4 were measured. Stroke outcomes were
measured at discharge, 3 and 12 months using the modified Rankin scale and modified Barthel Index as markers of
disability. Though we found that lower levels of free T3 were associated with worse prognosis at hospital discharge,
and at 3 and 12 months post-stroke, none of these outcomes held after multivariate analysis. Thus, it is likely that
thyroid hormones are associated with other factors that impact stroke outcomes, such as sex, age and stroke
etiology.
Conclusions: This study found that lower levels of free T3 were associated with poorer outcomes at hospital
discharge, and at 3 and 12 months post stroke, however, these associations diminished after correction for other
known predictors of stroke outcome. Thyroid hormones have a complex relationship with ischemic stroke and
stroke recovery, which merits further larger investigations.
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Stroke is the fifth leading cause of death and the primary
cause of long-term adult disability in the United States
[1]. Perturbations in the hypothalamus-pituitary-thyroid
(HPT) axis affect stroke risk and stroke outcomes.
Hypothyroidism can cause hypertension, hypercholester-
olemia, cardiac dysfunction, and both hypo- and hyperco-
agulability, all of which are risk factors for stroke [2–4].
Hyperthyroidism is also associated with atrial fibrillation,
which is a common cause of cardioembolic stroke [5].
The relationship between thyroid hormones and func-
tional outcomes post-stroke is complex. Current data
has shown that low T3 levels immediately following* Correspondence: lmccullough@uchc.edu
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stroke severity and mortality, and poorer functional out-
comes [6–8]. This is also true in critically ill hospitalized
patients who have non-thyroidal illness syndrome
(NTIS; or ‘euthyroid sick syndrome’), where T3 levels
are low, but TSH is normal [9–11]. NTIS patients have
poorer short-term prognosis and higher mortality rates
at 12 months compared to non-NTIS patients [6]. How-
ever, data regarding the association between TSH levels
and functional outcomes after stroke are conflicting
[12–15]. The association between TSH levels and stroke
outcome remains unclear, in part, because few studies
have looked at TSH, T3, and T4 values concurrently.
Doing so may be especially relevant in patients with
brain injury and perturbations in HPT signaling.
This study examines the association between thyroid
hormone levels (T3, T4, and TSH) and ischemic strokerticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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(mRS) and modified Barthel index (mBI) at hospital dis-
charge, and at 3 and 12 months.
Methods
Study setting and population
This study was conducted at an 868-bed community-
based teaching hospital with a Neurology Residency Pro-
gram. This center has The Joint Commission’s Gold Seal
of Approval and the American Heart Association’s Ad-
vanced certification as a comprehensive stroke center
and has an annual stroke admission rate of approxi-
mately 1000. This study was approved by the Institu-
tional Review Board.
Study protocol
Blood was collected from patients over 18 years of age
with radiologically confirmed acute ischemic stroke
(AIS) (n = 129) at 24 ± 6 h post-symptom onset under an
approved IRB from December 2011 to May 2013. Pa-
tients with active malignancy or treatment with immu-
nosuppressants were excluded from the study. Serum
levels of TSH, free T3 (fT3), and free T4 (fT4) were
quantified by solid-phase chemiluminescent immuno-
metric assay (R&D Systems, Minneapolis, MN).
Measurements
Trained nursing staff prospectively collected clinical and
patient information and entered it into the Stroke Center’s
database, which contains information regarding patient
presentation, stroke etiology, and outcome. Baseline
demographic information (age, sex, medical history, medi-
cation use) was collected. Risk factors such as history of
hypertension, atrial fibrillation, coronary artery disease,
previous stroke or transient ischemic attack, diabetes mel-
litus, hypercholesterolemia, cigarette smoking and alcohol
use were also collected. Primary outcomes were in-
hospital mortality and National Institutes of Health Stroke
Scale (NIHSS) score on admission. Secondary outcomes
included death or hospice after discharge, and modified
Rankin scale (mRS) and modified Barthel Index (mBI), at
3 and 12 months post-stroke. The mRS is a scale for
measuring the disability of patients post-stroke. It has a
scale of 0–6, with 0 designating no limitations or symp-
toms, 5 being severe disability requiring constant care,
and 6 being dead [16]. The mBI is a scale used to measure
performance in activities of daily living. It is scored on a
scale of 0–20 with 20 being independent and 0 being com-
pletely dependent [17].
Statistical analysis
Continuous data, such as age, are presented as means
(standard deviation). Non-normally distributed con-
tinuous and ordinal data are presented as medians(interquartile range) and were analyzed with non-
parametric tests (Spearman’s Rho). Categorical data are
presented as proportions, and group differences were
assessed with chi-square tests of proportion. Several
variables with non-normal distributions were dichoto-
mized and analyzed with chi-square test of proportions.
These included the mBI, dichotomized into “independ-
ent” (score of 15 or greater), or “dependent” (14 or
less), and mRS, dichotomized into “disabled” (score of 3
or greater) or no disability to slight disability, termed
“abled” (2 or less). A “poor outcome” composite meas-
ure was defined as death or disabled with an mBI ≤14
or a mRS ≥3 as defined above at 3 and 12 months after
AIS. A “favorable outcome” composite measure was de-
fined as mBI ≥15 or mRS ≤ 2. Significant findings iden-
tified in the univariate analyses that pertained to more
than one thyroid marker were reanalyzed using multi-
variable logistic regression to control for all significant
confounding variables. Thus, a unified list of predictive
factors was applied to all three thyroid markers in
multivariate analysis. This included atrial fibrillation
(AFIB), depression, urinary tract infection (UTI), intra-
arterial devices (IA), age and NIHSS on admission. The
criterion of statistical significance was set at 0.05. All
analyses were performed using Statistical Package for
the Social Science v14.
Results
Demographics
Patient demographics are listed in Table 1. Out of the
129 patients, 119 were classified as euthyroid (TSH be-
tween 0.27 and 4.20 microunits/L), 7 as hyperthyroid
(TSH < 0.27 microunits/L), and 3 as hypothyroid (TSH >
4.20 microunits/L).
Demographic associations
As expected TSH was inversely correlated with fT4,
though there was no significant correlation between
TSH and fT3. fT3 and age were inversely correlated, but
there was no significant association with age for TSH or
fT4. There was no significant difference between males
and females in TSH, fT4, or fT3 levels (Table 2).
Pre-stroke associations
Patients with low levels of fT3 had increased disability
at baseline indicated by higher pre-stroke mRS scores
(r = −0.393, p < 0.001) and lower mBI scores (r = 0.295,
p = 0.002) (Table 2).
Admission
The NIHSS on admission was inversely associated with
fT3 (R = −.191, p = 0.031), but not TSH or fT4. Hospital
mRS was inversely associated with TSH (R = −0.206, p =
0.019), and directly associated with fT4 (R = 0.176, p =
Table 1 Characteristics of study patients
Category
Age (y ± sd) 67.03 ± 14.474
Sex
Female 51 (39.5 %)
Male 78 (60.5 %)
Ethnicity
White 99 (76.7 %)
Black 12 (9.3 %)
Latino 15 (11.6 %)
Other 3 (2.3 %)
History of
HTN 106 (82.2 %)
Diabetes 46 (35.7 %)
Heart disease 44 (34.1 %)
Stroke 19 (14.7 %)
High cholesterol 91 (70.5 %)
Atrial fibrillation 31 (24 %)
Angina 0
Blood clots 4 (3.1 %)
Arthritis 16 (12.4 %)
Seizures 5 (3.9 %)
Dementia 4 (3.1 %)
Depression 17 (13.2 %)
Lung problems 8 (6.2 %)
Aspiration pneumonia 9 (7.0 %)
Aneurysm 0
UTI 20 (15.5 %)
Smoking 25 (19.4 %)
Alcohol 5 (3.9 %)
Drugs 2 (1.6 %)
Origin Location
Home 61 (4.3 %)
Community 16 (12.4 %)
Inpatient 1 (0.8 %)
Transfer patient 44 (34.1 %)
Facility 6 (4.7 %)
Characteristics of patients enrolled in this study including demographics, past
medical history, and origin location
HTN hypertension, UTI urinary tract infection
Table 2 Associations between thyroid hormones and patient




TSH NS NS R = −0.246*
Sex NS NS NS
Age NS R = −.332*** NS
Pre-stroke associations
Baseline mRS NS R = −0.393*** NS
Baseline mBI NS R = 0.295*** NS
Admission associations
Admission NIH NS R = −0.191* NS
Hospital mRS R = −0.206 NS R = 0.176*
Admission mBI NS NS NS
Other associations
Past medical history
Hypertension NS NS NS
Heart disease NS NS NS
Prior stroke NS NS NS
Diabetes NS NS NS
Depression NS NS NS
Alcohol use NS NS NS
Medications
Anti-platelets NS NS NS
Anticoagulants NS NS NS
Anti-hypertensives NS NS NS
Anti-cholesterol NS NS NS
Associations between thyroid hormones and demographics upon hospital
admission. Patients with low levels of fT3 had increased disability and poorer
pre-stroke function. NIH score on admission was inversely associated with fT3.
Hospital mRS was inversely associated with TSH and directly associated with
fT4. None of the thyroid hormones were associated with past medical history
of hypertension, heart disease, prior stroke, diabetes, depression, alcohol use,
or with the usage of anti-platelets, anti-coagulants, anti-hypertensives, or
anti-cholesterol medications
*p < 0.05; **p < 0.01; ***p < 0.001
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mBI score was unrelated to fT3, fT4, or TSH levels
(Table 2).
Outcome at discharge
Patients with lower TSH had significantly higher in hos-
pital mortality (p = 0.015). There was no association be-
tween hospital mortality and fT3 or fT4. However,patients who were alive at discharge had significantly
higher fT3 levels than patients who either died in hos-
pital or went to hospice (p = 0.01) (Table 3).
3 month outcomes
Low TSH was related to 3 month mortality (p = 0.036).
Patients who died at 3 months had lower TSH values
than those who were alive at 3 months. Higher 24 h fT3
levels were predictive of good outcome at 3 months as
measured by mBI > 15 (p = 0.004). In addition, patients
with a favorable composite outcome at 3 months had
higher TSH levels than those with a poor composite out-
come (Table 3). There was no association between out-




Death in hospital NS NS
Died 0.5245 (0.303–0.761)*
Alive 1.275 (0.75–1.9875)*
Death in hospital or hospice vs alive NS NS
Death or hospice 1.99 (1.74–2.475)*
Alive 2.47 (2.13–2.95)*
3 month outcomes
Death vs alive at 3 months NS NS
Death 0.66 (0.372–1.45)*
Alive 1.27 (0.75–2.11)*
Independence level NS NS
mBI > 15, independent 2.53 (2.24–2.99)**
mBI < 14, dependent 2.06 (1.85–2.6)**
Poor outcome, mRS > 3 or death 0.873 (0.586–1.48)*
Favourable outcome, mRS < 2 1.54 (0.6575–2.255)*
12 month outcomes
mRS score NS R = −0.268* NS
mBI > 15, independent 2.525 (2.26–2.965)*
mBI < 14, dependent 2.175 (1.865–2.823)*
Poor outcome, mRS > 3 or death 2.04 (1.825–2.485)***
Favourable outcome, mRS < 2 2.62 (2.32–2.97)***
Patients with better acute and long term outcomes had higher TSH levels, and higher fT3 levels at 3 and 12 months post-stroke. No associations were seen
between acute and long term outcomes with fT4
*p < 0.05; **p < 0.01; ***p < 0.001
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The same pattern was seen at 12 months. Patients with
the highest fT3 levels were the most likely to be inde-
pendent as measured by the mBI 1 year after ischemic
stroke (p = 0.042). This was confirmed by an inverse as-
sociation between mRS and fT3 levels, showing that the
higher the initial fT3, the better the outcome, even a
year after the index event (p = 0.042). Neither mBI nor
the mRS at 12 months was related to TSH or fT4 levels
(Table 3).
Other associations
There were differences in fT3 based on stroke etiology
determined with the TOAST classification. Patients with
small vessel disease had higher fT3 values than those withTable 4 Multivariate analysis
TSH: OR (95 % CI
Death in hospital or hospice 0.635 (0.250–1.61
3 month outcome, mRS > 3 or death vs mRS < 2 0.686 (0.398–1.18
3 month outcome, mBI > 15 vs mBI < 14 or death 0.707 (0.443–1.12
Multivariate regression results between thyroid hormones and acute and long-term
NIH on admission, thyroid markers were not associated with mortality or functionallarge vessel or cardioembolic stroke etiology (H(2) = 11.06,
p = 0.004) with a mean rank of 83 for small vessel disease,
59 for large vessel disease, and 53 for cardioembolic stroke
etiology.Multivariate
A multivariate logistic regression model was used to
control for the potential confounders identified in the
univariate analyses as described above. When controlling
for AFIB, depression, UTI, IA, age and NIH on admis-
sion, thyroid markers were not associated with mortality
or functional outcomes (Table 4), suggesting that thyroid
status is related to other risk factors rather than an inde-
pendent predictor of outcome.), P fT3: OR (95 % CI), P fT4: OR (95 % CI), P
3), NS 1.06 (0.569–1.974), NS 1.957 (0.323–11.872), NS
1), NS 0.517 (0.226–1.185), NS 1.574 (0.465–5.328), NS
7), NS 0.513 (.215–1.225), NS
outcomes post-stroke. When controlling for AFIB, depression, UTI, IA, age, and
outcomes
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This study is the first to look at TSH, fT3, and fT4 concur-
rently and their association with stroke severity and long
term functional outcomes. This study found that low TSH
and fT3 were associated with poor function at 3 months,
and that low TSH and fT3 were associated with higher
rates of death in the hospital. However, these results were
not seen in the multivariate analysis when other known
predictors of outcome such as stroke severity (NIHSS)
were controlled. This is likely due to the relatively small
sample size of the study, and the fact that the majority of
patients sampled were euthyroid. Though prior studies
have demonstrated an association between low T3 levels
and poor outcomes, it is likely that this study was under-
powered to detect an association. Outcomes at 12 months
were only available in a minority of patients. Future studies
with an increased number of patients with hyper- and
hypothyroidism and hypothyroidism with hormone re-
placement should be done to assess a wider range of thy-
roid values and outcomes. In addition, assessment of
hormone levels over multiple time points is needed to dem-
onstrate changes in thyroid status over time, as only one
time-point was evaluated here. However, the significant as-
sociation between thyroid hormone levels and outcome in
the univariate models suggest that this is worth pursuing
vigorously in larger studies, as strategies to replace thyroid
levels could be developed for therapeutic trials.
Although it is unknown whether administration of ex-
ogenous thyroid hormone in stroke patients improves out-
comes, administration of T3 resulted in increased mRNA
expression of reelin and brain-derived neurotrophic factor
in rats, both of which are important in nervous system re-
generation [18]. In hospital patient monitoring of thyroid
status may be important as higher levels of fT3 have been
associated with better functional outcomes. Therefore,
treatment to normalize and/or elevate fT3 values for pa-
tients presenting with NTIS could be beneficial to a pa-
tient’s recovery after acute ischemic stroke.
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